Skip to content

Released May 9, 2019, after the close

10-Q filed May 9, 2019, 39 days after period end · 0001564590-19-017941

Q1 2019 · 10-Q
Revenue$3.81M+230.2% vs Q1 2018+125.0% vs Q4 2018
Net Income-$5.10MN/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.29N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$5,696,000N/M
Operating Cash Flow-$10,924,000N/M
Free Cash Flowderived-$11,005,000—
Margins · derived
Operating margin-149.6%+788.5 pt vs Q1 2018
Net margin-134.0%+789.2 pt vs Q1 2018

What the release said

The release

Same quarter

MetricQ1 2019Q1 2018Q1 2017Q1 2016
Revenue$3.81M$1.15M$140.00K—
Net Income-$5.10M-$10.64M-$5.88M-$5.91M
EPS Diluted-$0.29-$0.74-$21.60-$21.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR